Roy Suryo
The availability of prescription-strength co-codamol in Scotland is expected to remain limited until at least June, the Scottish government has confirmed, a situation arising from a UK-wide shortage of the strongest form of this commonly prescribed painkiller. The specific dosage affected is the 30/500mg formulation, a deficiency directly linked to delays in the Indian government’s authorisation process for importing essential ingredients required for its manufacture. In response to this ongoing crisis, the Scottish government has assured that alternative treatment options will be proactively offered to all patients impacted by these supply disruptions. However, despite the availability of alternative medications, some health boards have raised concerns, warning that no single alternative can fully absorb the anticipated surge in demand, potentially leading to further strain on healthcare resources and patient well-being.
BBC Scotland News has been contacted by numerous individuals who rely on co-codamol for chronic pain management, with several reporting that their doctors have informed them of its unavailability until June. Jocelin Harrison, a resident of NHS Lanarkshire, received a notification from her health board last week advising her to commence a gradual reduction of her daily dosage, lowering it by one tablet per week to mitigate the risks of sudden withdrawal symptoms. Ms. Harrison has been dependent on co-codamol for over three decades, a necessity stemming from the persistent pain following five extensive spinal surgeries. She expressed her profound distress and anxiety, stating, "The only advice I’ve been given so far was to reduce the tablets and try to manage my withdrawal symptoms. I was not offered any other advice or possible replacement pain killers and it’s a great worry for me and other chronic pain sufferers throughout Scotland and the UK." Her experience highlights the deep-seated reliance many patients have on this medication and the significant emotional and physical toll the shortage is imposing.
Co-codamol, a combination medication, comprises the opiate codeine and paracetamol. Due to its codeine content, it possesses the potential for dependence and addiction. The drug is available in three distinct strengths, each containing 500mg of paracetamol, but varying amounts of codeine: 8mg, 15mg, or 30mg. While the lowest strength (8mg codeine) is readily available over-the-counter at pharmacies, the higher strengths (15mg and 30mg codeine) necessitate a prescription from a medical practitioner. Patients who are currently taking co-codamol have been strongly advised to taper their usage gradually to avoid experiencing withdrawal symptoms, which can manifest as severe headaches, nausea, profuse sweating, and potentially an exacerbation of their existing pain, particularly for those who use the medication most frequently.
A stark warning posted on the NHS Lanarkshire website elaborates on the severity of the situation. It states, "there are other strengths of co-codamol tablets but there are not enough supplies of these to move everyone onto them." This critical announcement further advises that, with the exception of cancer patients undergoing treatment, all individuals currently prescribed co-codamol should initiate a phased reduction in their intake until complete cessation is achieved. The health board has also indicated that no new patients will be prescribed co-codamol until supplies are replenished and return to normal levels, a timeline tentatively set for June, though this date is not guaranteed. This policy shift underscores the urgent need to conserve existing, limited stock for those who depend on it most critically.
In parallel, NHS Grampian has issued a similar advisory, directing pharmacists to "use professional judgement to prioritise stocks and quantities supplied to patients." While this guidance acknowledges the supply challenges, it falls short of the explicit instruction provided by NHS Lanarkshire for current users to begin reducing their dosage. The underlying cause of these widespread supply issues has been identified as the delayed authorisation by the Indian government concerning the import of codeine-based active pharmaceutical ingredients (APIs), which are fundamental components in the manufacturing of co-codamol. This bureaucratic bottleneck in a key global supplier country has created a ripple effect, impacting medication availability across the United Kingdom.
Alison Strath, the Scottish government’s chief pharmaceutical officer, has acknowledged the gravity of the situation, stating, "Medicine supply is a matter reserved to the UK government. We are aware of limited supplies of the commonly prescribed pain-relief medicine co-codamol and know this may cause some concern." She confirmed that supply issues are anticipated to persist until June 2026 and reiterated that the Scottish government is in continuous dialogue with the UK government, seeking assurances that all possible measures are being taken to expedite a resolution. Strath added, "We have issued advice to health boards to ensure patients affected receive accurate information and clear advice. We would ask that patients do not contact their GP practice or community pharmacy – instead, work is underway to identify those who may be affected, and they will be offered alternative treatment options." This proactive approach aims to manage patient expectations and ensure that those most in need are identified and supported.
The UK government’s Department of Health and Social Care has commented on the broader medicine supply landscape, asserting that "the vast majority" of licensed medicines remain in good supply. However, they admitted awareness of the co-codamol tablet shortages, attributing them to "manufacturing issues." A spokesperson stated, "We are aware that co-codamol tablets are currently in limited supply due to manufacturing issues, and are working closely with suppliers to resolve current disruptions and ensure continuity of supply. We are also engaged with NHS specialist clinicians and have issued comprehensive guidance on how to manage patients during this time, including advice on alternative preparations." This indicates a coordinated effort at the UK level to address the crisis, involving collaboration with manufacturers, healthcare providers, and clinical experts.
The production of generic, non-branded medications, such as co-codamol 30/500mg, is predominantly carried out in manufacturing hubs like China and India. Recent statistics from manufacturers, such as Actiza, highlight the extensive global reach of these pharmaceutical exports, with products being distributed to over 200 countries worldwide. This globalised supply chain, while generally efficient, also makes it vulnerable to disruptions in specific regions or due to international regulatory processes. The current situation with co-codamol underscores the interconnectedness of global pharmaceutical production and the potential for localised issues to have far-reaching consequences for patient access to essential medicines. The reliance on a limited number of manufacturing bases for critical APIs means that any impediment in these supply lines can create significant challenges for healthcare systems worldwide, necessitating robust contingency planning and diversification of sourcing where possible. The extended timeline for resolution also points to the complexity of rectifying these manufacturing and import issues, requiring sustained effort and international cooperation to ensure a stable and reliable supply of co-codamol for patients in Scotland and beyond.
Ramos Leo
atisusanti
Nakalama John
George Anjay